Publications by authors named "S A Luykx"
Article Synopsis
- Immune checkpoint inhibition (ICI) combined with chemotherapy is the standard treatment for stage II-III triple-negative breast cancer, but the effectiveness of ICI alone remains unclear.
- The adaptive BELLINI trial found that short-term ICI treatments led to immune activation in a significant portion of patients, correlating immune response with tumor-infiltrating lymphocytes.
- A new cohort is being studied with patients who have high levels of these lymphocytes; early results show a notable rate of major and complete pathological responses post-treatment, suggesting that neoadjuvant ICI could be a promising approach without chemotherapy.
Background: The prognosis of malignant gliomas remains poor. In recurrent disease, chemotherapy can be considered.
Patients And Methods: In this phase II study we determined the anti-tumour efficacy of paclitaxel 200 mg/m2 in a three-hour intravenous infusion every three weeks in chemonaïve patients with recurrent high-grade glioma in terms of response, survival, and quality of life.
Ten patients with locally advanced breast cancer were given doxorubicin i.v., and an incision biopsy was subsequently taken.
View Article and Find Full Text PDF